Skip to main content
Fig. 8 | Cancer Cell International

Fig. 8

From: Integrative evaluation and experimental validation of the immune-modulating potential of dysregulated extracellular matrix genes in high-grade serous ovarian cancer prognosis

Fig. 8

Implications of ECMscore for immunotherapy and chemotherapy. (A) Correlation analysis between ECMscore and TIDE scores in GSE140082 and TCGA-OV cohorts. (B) Comparison of IPS between low- and high-ECMscore groups stratified by PD-1 and CTLA4 expression. (C) Relationship between ECMscore groups and immunotherapy responses using the TIDE algorithm. (D) Kaplan-Meier analysis estimating OS in different ECMscore groups in the IMvigor cohort. (E) Distribution of ECMscore in patients with distinct immunotherapy responses (left) and immunophenotypes (right) in the IMvigor cohort. (F) Kaplan-Meier analysis estimating OS in different ECMscore groups in Nathanson’s cohort. (G) Distribution of ECMscore in patients with varying immunotherapy responses in Nathanson’s cohort. (H) Kaplan-Meier analysis estimating OS in different ECMscore groups in the GSE100797 cohort. (I, J) Distribution of ECMscore in patients with diverse immunotherapy responses in the GSE100797(I) and GSE35640 cohort. (K) Correlation analysis between ECMscore and IC50 values of candidate drugs in TCGA-OV cohort. (L) Comparison of IC50 values of candidate drugs between low- and high-ECMscore groups in TCGA-OV cohort

Back to article page

Cancer Cell International

ISSN: 1475-2867

Contact us